Oncomatryx Biopharma
Ignacio Garcia-Ribas is a seasoned medical professional with extensive experience in oncology drug development. Currently serving as Senior Medical Director at Oncomatryx Biopharma since March 2022 and as Senior Consultant and Chief Medical Officer at Cantargia AB since February 2020, Ignacio has held significant roles in multiple organizations. Prior positions include Senior Medical Director at Takeda Oncology, where Ignacio acted as Global Clinical Lead on several Phase 1/2 programs focused on immune-oncology, and Project Head at Sanofi overseeing early oncology pipeline molecules and clinical trials. Ignacio's career began at Eli Lilly and Company, contributing to early drug development in oncology. Ignacio holds a PhD in Cancer Gene Therapy and is a specialist in Medical Oncology, supported by an MD from Universidad Autónoma de Madrid.
This person is not in any teams
Oncomatryx Biopharma
Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumorinvasiveness, drug resistance and immunosuppression.Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.